(NASDAQ: NBIX) Neurocrine Biosciences's forecast annual revenue growth rate of 12.09% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 121.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.17%.
Neurocrine Biosciences's revenue in 2025 is $2,682,700,000.On average, 31 Wall Street analysts forecast NBIX's revenue for 2025 to be $290,442,698,274, with the lowest NBIX revenue forecast at $271,398,909,956, and the highest NBIX revenue forecast at $303,304,733,316. On average, 30 Wall Street analysts forecast NBIX's revenue for 2026 to be $342,788,189,724, with the lowest NBIX revenue forecast at $303,504,144,712, and the highest NBIX revenue forecast at $382,072,234,736.
In 2027, NBIX is forecast to generate $372,001,959,238 in revenue, with the lowest revenue forecast at $295,029,160,382 and the highest revenue forecast at $451,567,106,242.